PASCAGOULA, Miss., June 13, 2022 (GLOBE NEWSWIRE) — All-domain defense and technologies partner HII (NYSE:HII) announced today the successful demonstration of capabilities enabling HII-built amphibious warships to launch, operate with and recover HII-built large-diameter unmanned underwater vehicles (LDUUV).
Addex Therapeutics Concludes Enrollment In Part 1 Of Phase 2 Study of ADX71149 For Epilepsy. Independent Interim Review Committee’s Outcome And Next Steps For The Program Are Expected By The End Of Q1 2023
The trial is being conducted by Janssen Pharmaceuticals Inc part of Johnson & Johnson. Based on the outcome of the review and recommendations from the IRC, Janssen will evaluate the next steps for
